ライフサイエンスコーパス: relapsing-remitting

1 We prospectively recruited 20 relapsing-remitting, 15 secondary progressive multiple s

2 PHOMS were present in 16% of patients with relapsing-remitting, 16% of patients with progressive, a

3 7 healthy control subjects, 27 patients with relapsing-remitting, 23 with secondary-progressive and 2

4 : 119 (72%) had multiple sclerosis [94 (57%) relapsing-remitting, 25 (15%) secondary progressive], 45

5 lthy controls and 122 patients comprising 58 relapsing-remitting, 28 primary progressive and 36 secon

6 with a clinically isolated syndrome, 29 with relapsing-remitting, 28 with secondary-progressive and 2

7 ars, disease duration 14.6+/-10 years; 67.8% relapsing-remitting, 28% secondary progressive and 4.2%

8 tients (22 clinically isolated syndrome, 198 relapsing remitting, 39 secondary progressive, 31 primar

9 6 +/- 1.39 versus 49.13 +/- 1.19, P < 0.01), relapsing-remitting (48.86 +/- 2.89 versus 47.44 +/- 2.7

10 icipants included 36 individuals with MS (30 relapsing-remitting, 6 secondary or primary progressive)

11 ts (31 clinically isolated syndrome, and 416 relapsing-remitting, 84 secondary progressive, and 73 pr

12 Forty-three patients with relapsing remitting and 28 with secondary progressive mu

13 ith distance from the ventricles in both the relapsing remitting and secondary progressive multiple s

14 d degenerating brain and spinal cord in both relapsing-remitting and progressive forms of MS and may

15 Individuals suffering from relapsing-remitting and secondary progressive MS had sig

16 cervical spinal cord of patients with early relapsing-remitting and secondary progressive multiple s

17 ealthy donors and MS patients in the initial relapsing-remitting and subsequent secondary-progressive

18 nearest the subpial surfaces for those with relapsing-remitting and the central canal CSF surface in

19 rrently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple s

20 Behcet disease is a chronic, relapsing-remitting autoinflammatory syndrome with a str

21 This case of relapsing-remitting AVWS demonstrates the use of VWFpp:A

22 fected with M. amphoriforme manifesting as a relapsing-remitting bacterial load, interspersed by peri

23 em traditionally characterized by an initial relapsing-remitting clinical course and focal inflammato

24 The case is presented due to the relapsing-remitting clinical course of the disease that

25 and white matter of the CNS, resulting in a relapsing-remitting CNS autoimmunity.

26 ed syndrome (coefficient = -0.32, P = 0.03), relapsing-remitting (coefficient = -0.48, P < 0.01), sec

27 2 of 268 (94.0%) patients who maintained the relapsing-remitting course and 58 of 66 (87.8%) patients

28 Over 9 mo, these mice exhibited a relapsing-remitting course of hind-limb clasping with th

29 Despite varying prior severity of relapsing-remitting course, all participants experienced

30 secondary progressive disease and 14 with a relapsing remitting disease course) underwent T1- and T2

31 Because atopic dermatitis (AD) is a relapsing remitting disease, assessing long-term control

32 s (MS) is a neuroinflammatory disease with a relapsing-remitting disease course at early stages, dist

33 Patients with MS with relapsing-remitting disease course or SP were included.

34 ression was more common in younger patients, relapsing-remitting disease course, and after a smaller

35 y of myelin-reactive CD4 T cells that elicit relapsing-remitting disease have not been quantified.

36 d by a global increasing incidence driven by relapsing-remitting disease in females.

37 e determined that pEVs induced a spontaneous relapsing-remitting disease phenotype in MOG(35-55)-immu

38 t decisions are based on what is known about relapsing-remitting disease remains unclear.

39 AZD1480 delays disease onset of PLP-induced relapsing-remitting disease, reduces relapses and dimini

40 ocyte ratio was observed in MS patients with relapsing-remitting disease.

41 nantly of younger patients and patients with relapsing-remitting disease.

42 ry and secondary progressive disease than in relapsing-remitting disease.

43 g the first relapse in a SJL animal model of relapsing-remitting EAE abrogated clinical disease, infl

44 of Del-1-Fc ameliorated clinical relapse in relapsing-remitting EAE.

45 IL-27-conditioned DCs suppressed established relapsing-remitting EAE.

46 ssion (C-PRO group) and chronic disease with relapsing-remitting episodes (C-RELAP group).

47 preclinically, could suppress progression of relapsing-remitting experimental autoimmune encephalomye

48 ition of system Xc(-) attenuates chronic and relapsing-remitting experimental autoimmune encephalomye

49 Moreover, guanabenz ameliorates relapse in relapsing-remitting experimental autoimmune encephalomye

50 causal role of IL-11 in the exacerbation of relapsing-remitting experimental autoimmune encephalomye

51 d progressive, as well as PLP138-151-induced relapsing-remitting experimental autoimmune encephalomye

52 BE1 mutations can cause an early adult-onset relapsing-remitting form of polyglucosan body disease di

53 d on the 2010 McDonald criteria (34 with the relapsing-remitting form, 2 with clinically isolated syn

54 ges were significant in both progressive and relapsing-remitting forms of the disease and correlated

55 , whereas the classifier that differentiates relapsing-remitting from progressive MS achieved a valid

56 models of autoimmunity, type 1 diabetes and relapsing-remitting immune-mediated demyelination.

57 Multiple sclerosis (MS) is a chronic relapsing-remitting inflammatory disease of the central

58 males with progressive disease compared with relapsing-remitting males (RRMS) and female MS subjects,

59 disease relapses and remissions in the SJL/J-relapsing-remitting model of EAE, and could comparably a

60 Using a relapsing-remitting model of EAE, here we demonstrate th

61 se episode alleviated clinical symptoms in a relapsing-remitting model of proteolipid protein139-151-

62 of Gli1 improves the functional outcome in a relapsing/remitting model of experimental autoimmune enc

63 d in MS by comparing the fecal microbiota in relapsing remitting MS (RRMS) (n = 31) patients to that

64 ith secondary progressive MS [SPMS], 27 with relapsing remitting MS [RRMS]) and 30 healthy volunteers

65 ants with secondary progressive MS than with relapsing-remitting MS (3.6 lesions/year +/- 4.2 vs 1.1

66 Participants were 31 patients with Relapsing-Remitting MS (mean age = 44.323 +/- 13.149; me

67 ectroscopic imaging data in 46 patients with relapsing-remitting MS (median disease duration, 0.8 yea

68 Case series of patients with relapsing-remitting MS (n = 123) or secondary-progressiv

69 ts with a diagnosis of either PPMS (n = 16), relapsing-remitting MS (n = 20), or benign MS (n = 20) a

70 Patients with active relapsing-remitting MS (n=20) and healthy controls (n=8)

71 ion (p=0.034), and relapses in patients with relapsing-remitting MS (p=0.008) during the study.

72 expression is reduced in CD4(+) T cells from relapsing-remitting MS (RR-MS) patients during relapse.

73 can serve as a biomarker of regeneration in relapsing-remitting MS (RRMS) and whether disease-modify

74 Patients with relapsing-remitting MS (RRMS) or clinically isolated syn

75 ethylenediaminetetraacetic acid plasma in 10 relapsing-remitting MS (RRMS) patients, 9 secondary prog

76 secondary-progressive MS (SPMS) patients, 12 relapsing-remitting MS (RRMS) patients, and 14 matched h

77 d from clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS) to SPMS.

78 majority of plaques in acute monophasic and relapsing-remitting MS (RRMS) were active.

79 were reconstructed from diffusion data in 58 relapsing-remitting MS (RRMS), 28 primary progressive MS

80 ulatory (EDSS scores <=3.5), all of whom had relapsing-remitting MS (RRMS), 3 (4%) had RRMS and EDSS

81 odic relapses followed by remissions, called relapsing-remitting MS (RRMS).

82 inically isolated syndrome (CIS) and 69 with relapsing-remitting MS (RRMS; mean age: CIS: 31.4 +/- 9.

83 nal fluid (CSF) and blood from subjects with relapsing-remitting MS (RRMS; n = 12), other neurologic

84 in progressive MS (r = 0.67; p < 0.001) than relapsing-remitting MS (RRMS; r = 0.33; p = 0.007).

85 nd April 2019, 120 patients with MS (58 with relapsing-remitting MS [RRMS] and 62 with progressive MS

86 atic carriers of HTLV-1 (AC), 47 HAM/TSP, 74 relapsing-remitting MS [RRMS], 17 secondary progressive

87 (52 clinically isolated syndrome [CIS], 196 relapsing-remitting MS [RRMS], 34 progressive MS [PMS]),

88 terials and Methods Twenty participants with relapsing-remitting MS and 13 with secondary progressive

89 In a prospective study, 326 patients with relapsing-remitting MS and 163 patients with progressive

90 Eighteen patients with relapsing-remitting MS and 17 healthy controls were cogn

91 Twenty-five patients with relapsing-remitting MS and 20 healthy control subjects u

92 Forty-eight patients with relapsing-remitting MS and 24 control subjects underwent

93 Fifty-seven consecutive patients with relapsing-remitting MS and 30 healthy, age-matched contr

94 Twenty-six patients with relapsing-remitting MS and 32 healthy control subjects f

95 One hundred patients with relapsing-remitting MS and 50 healthy controls.

96 diagnosis of clinically isolated syndrome or relapsing-remitting MS and a minimum of 7 years of prosp

97 sability Status Scale score of 3.5 to 6.5 or relapsing-remitting MS and an Expanded Disability Status

98 nce images were acquired from 133 women with relapsing-remitting MS and analyzed using voxel-based mo

99 eters to explain IPS and EF in patients with relapsing-remitting MS and confirms the central role of

100 the lateral funiculi and gray matter (GM) in relapsing-remitting MS and GM atrophy in patients with p

101 mean age 33.4 yrs) with clinically definite, relapsing-remitting MS and mild disability (EDSS - Expan

102 written informed consent, six patients with relapsing-remitting MS and six healthy control subjects

103 Whereas results were similar for relapsing-remitting MS cases (RRMS), those developing pr

104 ters in 21 countries examining patients with relapsing-remitting MS commencing DMTs (or clinical moni

105 ognitive performance of 99 clinically stable relapsing-remitting MS for whom data from four consequen

106 onal cohort study included 312 patients with relapsing-remitting MS in 2 independent cohorts (72 pati

107 alpha4 integrin, is effective against active relapsing-remitting MS in adults.

108 eased in patients with clinically definitive relapsing-remitting MS in comparison with healthy contro

109 t study, 14 healthy control participants, 18 relapsing-remitting MS multiple sclerosis ( RRMS relaxin

110 Disease course was classified as CIS, relapsing-remitting MS or secondary progressive MS (SPMS

111 e measured in CD14+ monocytes from untreated relapsing-remitting MS patients and compared to healthy

112 ssessed in a training set of 334 consecutive relapsing-remitting MS patients and in an independent va

113 Sixty-six (19.7%) relapsing-remitting MS patients changed their clinical c

114 volume suitably explains the probability of relapsing-remitting MS patients evolving into the progre

115 to analyze data from a large cohort of 1,697 relapsing-remitting MS patients in British Columbia, Can

116 In the present study, 15 relapsing-remitting MS patients receiving 1,000 mg of ri

117 Ten relapsing-remitting MS patients were studied using the T

118 Relapsing-remitting MS patients who developed PML under

119 second independent cohort of untreated early relapsing-remitting MS patients.

120 s and in an independent validation set of 84 relapsing-remitting MS patients.

121 Data on 201 pregnant women with relapsing-remitting MS were collected prospectively from

122 the phase 2 studies) and diagnosed as having relapsing-remitting MS were eligible to participate in t

123 18-60 years in phase 2 study) diagnosed with relapsing-remitting MS were included.

124 Additionally, patients with relapsing-remitting MS were treated with narrowband UVB

125 Participants included patients with relapsing-remitting MS who were switching therapy to fin

126 creased in peripheral blood of patients with relapsing-remitting MS with a high disease score.

127 6 with clinically isolated syndrome, 42 with relapsing-remitting MS) and 23 control subjects underwen

128 onset (clinically isolated syndrome [CIS] or relapsing-remitting MS) and were also compared to two ot

129 summarise emerging injectable therapies for relapsing-remitting MS, and discuss pharmacological mech

130 either clinically isolated syndrome (CIS) or relapsing-remitting MS, as well as for 15 age- and sex-m

131 d July 7, 2016, a total of 110 patients with relapsing-remitting MS, at least 2 relapses while receiv

132 age, shorter durations of MS, female gender, relapsing-remitting MS, higher educational attainment an

133 Among patients with relapsing-remitting MS, initial treatment with fingolimo

134 ing tool for identifying novel therapies for relapsing-remitting MS, it has proven to be less success

135 Among patients with relapsing-remitting MS, nonmyeloablative hematopoietic s

136 In this preliminary study of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared

137 the disease activity, among 99 patients with relapsing-remitting MS, who underwent blinded clinical a

138 d with worsening of disease in patients with relapsing-remitting MS.

139 play a role in the inflammatory response in relapsing-remitting MS.

140 n at the same doses shown to be effective in relapsing-remitting MS.

141 ognitive decline in a group of subjects with relapsing-remitting MS.

142 ar to that noted in a trial in patients with relapsing-remitting MS.

143 cal efficacy of these drugs in patients with relapsing-remitting MS.

144 al-appearing white matter volume (P=.005) in relapsing-remitting MS.

145 atients who satisfy traditional criteria for relapsing-remitting MS.

146 e therapeutic target for patients with early relapsing-remitting MS.

147 he approval of IFN-beta for the treatment of relapsing-remitting MS.

148 174 relapsing-remitting MS/CIS patients were included in thi

149 XA1 to influence T cell effector function in relapsing/remitting MS (RRMS), an autoimmune disease sus

150 FTY720 is a treatment for relapsing remitting multiple sclerosis (MS).

151 ntegrity of processing of structural RNAs in relapsing remitting multiple sclerosis (RRMS) and other

152 rom the cerebrospinal fluid of patients with relapsing remitting multiple sclerosis (RRMS) have highe

153 progressive multiple sclerosis compared with relapsing remitting multiple sclerosis group, and these

154 Serum IL-21 from 141 individuals with relapsing remitting multiple sclerosis was measured usin

155 Thirty-nine patients with relapsing remitting multiple sclerosis, at high risk of

156 were enrolled in this study, 24 patients had relapsing remitting multiple sclerosis, six had progress

157 s, and more so in secondary progressive than relapsing remitting multiple sclerosis, tissue structura

158 t approved oral therapy for the treatment of relapsing remitting multiple sclerosis.

159 lications for the diagnosis and treatment of relapsing remitting multiple sclerosis.

160 ins the most widely prescribed treatment for relapsing remitting multiple sclerosis.

161 ormalities between secondary progressive and relapsing remitting multiple sclerosis.

162 the CSF of progressive patients compared to relapsing remitting multiple sclerosis.

163 and efficacy of amiselimod in patients with relapsing- remitting multiple sclerosis.

164 3 years disease duration), 18 subjects with relapsing-remitting multiple sclerosis (>/= 4 years dise

165 -progressive (49.3 +/- 8.0 mM) compared with relapsing-remitting multiple sclerosis (43.0 +/- 8.5 mM,

166 Patients with relapsing-remitting multiple sclerosis (age 18-65 years,

167 rimary and secondary-progressive compared to relapsing-remitting multiple sclerosis (coefficients = -

168 atients with clinically isolated syndrome or relapsing-remitting multiple sclerosis (Expanded Disabil

169 Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) is an o

170 e cerebrospinal fluid of patients with early relapsing-remitting multiple sclerosis (MS) and in activ

171 n the brains and spinal cords of people with relapsing-remitting multiple sclerosis (MS) and progress

172 des of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a

173 Available treatment options for relapsing-remitting multiple sclerosis (MS) have expande

174 The use of natalizumab for highly active relapsing-remitting multiple sclerosis (MS) is influence

175 Unexpectedly, progressive and relapsing-remitting multiple sclerosis (MS) patients hav

176 on medications and disease progression among relapsing-remitting multiple sclerosis (MS) patients in

177 Patients who develop relapsing-remitting multiple sclerosis (MS) present with

178 No current therapy for relapsing-remitting multiple sclerosis (MS) results in s

179 iety of human autoimmune diseases, including relapsing-remitting multiple sclerosis (MS), in which in

180 ical and MRI activity in adult patients with relapsing-remitting multiple sclerosis (MS).

181 acetate therapy on B cells in patients with relapsing-remitting multiple sclerosis (MS).

182 n placebo-controlled phase II/III studies of relapsing-remitting multiple sclerosis (MS).

183 to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS).

184 ts with clinically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progr

185 ger-type lesion' in an independent cohort of relapsing-remitting multiple sclerosis (RRMS) and AQP4-a

186 cting fingolimod (FTY) treatment response in relapsing-remitting multiple sclerosis (RRMS) are lackin

187 TCR stimulation is impaired in subjects with relapsing-remitting multiple sclerosis (RRMS) because of

188 tokine polarization profile in patients with relapsing-remitting multiple sclerosis (RRMS) by high-di

189 umab is a newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe,

190 mbulatory function in disabled subjects with relapsing-remitting multiple sclerosis (RRMS) or seconda

191 e total circulating exosome transcriptome in relapsing-remitting multiple sclerosis (RRMS) patients a

192 e previously showed that memory B cells from relapsing-remitting multiple sclerosis (RRMS) patients e

193 Many JC virus antibody-positive relapsing-remitting multiple sclerosis (RRMS) patients w

194 (CSF) samples collected over 12 months from relapsing-remitting multiple sclerosis (RRMS) patients.

195 The transition from relapsing-remitting multiple sclerosis (RRMS) to seconda

196 le SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosis (RRMS), oral laqu

197 cetate (GA) are widely used in patients with relapsing-remitting multiple sclerosis (RRMS).

198 factors with long-term clinical outcomes in relapsing-remitting multiple sclerosis (RRMS).

199 odulator, for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

200 ta has been used as a first-line therapy for relapsing-remitting multiple sclerosis (RRMS).

201 long-lasting disease activity suppression in relapsing-remitting multiple sclerosis (RRMS).

202 s normal aging, or can be distinguished from relapsing-remitting multiple sclerosis (RRMS).

203 Participants were patients with relapsing-remitting multiple sclerosis 18 to 55 years ol

204 l trials (Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis [AFFIRM], Safety

205 a control cohort of neurologic autoimmunity (relapsing-remitting multiple sclerosis [MS] n = 110, HD

206 ion With Interferon Beta-1a in Patients With Relapsing-Remitting Multiple Sclerosis [SENTINEL], and I

207 al, we enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one

208 During the clinical relapse of both, relapsing-remitting multiple sclerosis and neuromyelitis

209 58 years) with relapsing multiple sclerosis (relapsing-remitting multiple sclerosis and secondary pro

210 atents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, cre

211 their effects on disability in patients with relapsing-remitting multiple sclerosis are maintained an

212 ratio values in the outer cord were lower in relapsing-remitting multiple sclerosis compared with cli

213 DMTs by comparing a cohort of patients with relapsing-remitting multiple sclerosis enrolled in the U

214 ed cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing rela

215 trial, patients aged 18-60 years with active relapsing-remitting multiple sclerosis from 84 centres i

216 In 140 eyes from 70 patients having relapsing-remitting multiple sclerosis from January 2011

217 d data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase a

218 In the clinically isolated syndrome and relapsing-remitting multiple sclerosis groups, outer cor

219 tive disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis have been license

220 at have regulatory approval for treatment of relapsing-remitting multiple sclerosis have little or no

221 igher in secondary-progressive compared with relapsing-remitting multiple sclerosis in cortical grey

222 Analysis of pEVs from relapsing-remitting multiple sclerosis patients also ide

223 nd extra-cellular sodium concentration in 19 relapsing-remitting multiple sclerosis patients and 17 h

224 xonal analysis could define axonal damage in relapsing-remitting multiple sclerosis patients earlier

225 nd 4-6 and 18-26 mo Tecfidera-treated stable relapsing-remitting multiple sclerosis patients using mu

226 m safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients.

227 312 on MRI Lesion Given Once Daily) Study in relapsing-remitting multiple sclerosis provides evidence

228 disagreement among devices in patients with relapsing-remitting multiple sclerosis regarding the ON

229 Subjects with relapsing-remitting multiple sclerosis showed a greater

230 , phase 3 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare dacliz

231 The mechanism underlying the progression of relapsing-remitting multiple sclerosis to secondary prog

232 olimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to

233 Women aged 18-50 years with relapsing-remitting multiple sclerosis were randomly ass

234 autoimmune encephalomyelitis (EAE) model of relapsing-remitting multiple sclerosis when administered

235 The drug might be an effective treatment for relapsing-remitting multiple sclerosis with less frequen

236 ggestive of CNS demyelination and typical of relapsing-remitting multiple sclerosis, a complete neuro

237 Eligible patients were aged 18-55 years, had relapsing-remitting multiple sclerosis, and had complete

238 ears old) with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive

239 ging has been examined in small cohorts with relapsing-remitting multiple sclerosis, but has not been

240 than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy

241 Among patients with relapsing-remitting multiple sclerosis, daclizumab HYP s

242 lusion criteria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one

243 As treatment for relapsing-remitting multiple sclerosis, glatiramer aceta

244 A) is widely prescribed for the treatment of relapsing-remitting multiple sclerosis, however, the mec

245 ns is the underlying pathological process in relapsing-remitting multiple sclerosis, the gradual accu

246 In patients with relapsing-remitting multiple sclerosis, treatment with a

247 a woman in her late 30s with a diagnosis of relapsing-remitting multiple sclerosis, who continued to

248 tified adult patients (aged >=18 years) with relapsing-remitting multiple sclerosis, with at least 6

249 ligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingol

250 Fingolimod is an effective treatment for relapsing-remitting multiple sclerosis.

251 negative prognostic factor in patients with relapsing-remitting multiple sclerosis.

252 rferon beta-1a (IFNbeta-1a) in patients with relapsing-remitting multiple sclerosis.

253 d for the treatment of people suffering from relapsing-remitting multiple sclerosis.

254 lockade on Treg homeostasis in patients with relapsing-remitting multiple sclerosis.

255 erapy approved for treatment of relapsing or relapsing-remitting multiple sclerosis.

256 ing agent in the management of patients with relapsing-remitting multiple sclerosis.

257 al effects on relapse rates in patients with relapsing-remitting multiple sclerosis.

258 the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis.

259 al and MRI disease activity in patients with relapsing-remitting multiple sclerosis.

260 ort further assessment of daclizumab HYP for relapsing-remitting multiple sclerosis.

261 mmunomodulator approved for the treatment of relapsing-remitting multiple sclerosis.

262 ephalomyelitis (EAE) that mirror chronic and relapsing-remitting multiple sclerosis.

263 more efficacious than either agent alone in relapsing-remitting multiple sclerosis.

264 response to interferon beta in patients with relapsing-remitting multiple sclerosis.

265 the central nervous system of patients with relapsing-remitting multiple sclerosis.

266 the first mAb approved for the treatment of relapsing-remitting multiple sclerosis.

267 milar effects on annualised relapse rates in relapsing-remitting multiple sclerosis.

268 rug Administration approved for treatment of relapsing-remitting multiple sclerosis.

269 ation due to adverse events in patients with relapsing-remitting multiple sclerosis?

270 he CSF of multiple sclerosis patients with a relapsing remitting (n = 15) or a progressive (secondary

271 ation reflected behaviour in the subgroup of relapsing remitting patients (rho = 0.74, P = 0.008).

272 ctions of white matter lesion enlargement in relapsing remitting patients and is associated with grea

273 ohort, and by 31% (MLM) and 14% (Markov) for relapsing remitting patients.

274 3.6 +/- 2.7% and 2.9 +/- 2.4%), compared to relapsing-remitting patients (1.6 +/- 2.1%, both P < 0.0

275 ve MS patients are immunologically closer to relapsing-remitting patients as compared with patients w

276 cretion in urine samples from a cohort of 70 relapsing-remitting patients with MS who were followed f

277 quency was higher in progressive compared to relapsing-remitting patients, with significant bilateral

278 reduced in secondary progressive relative to relapsing-remitting patients.

279 However, duration of the relapsing-remitting phase did not influence the times fr

280 ity and related clinical relapses during the relapsing-remitting phase of the disease.

281 ent disease-modifying agents for its initial relapsing-remitting phase, these therapies show limited

282 e with a clinically isolated syndrome (CIS), relapsing remitting (RR) and secondary progressive (SP)

283 Among 806 patients with relapsing remitting (RR) onset MS from the London Ontari

284 We investigated this in people with relapsing-remitting (RR) and secondary progressive (SP)

285 ate neuroinflammation at different phases of relapsing-remitting (RR) experimental autoimmune encepha

286 sed DNA methylation in the CD4(+) T cells of relapsing-remitting (RR) MS patients compared to healthy

287 raphically matched normal controls (NC), and relapsing-remitting (RR) MS patients, also matched with

288 copy, we analysed the lipoprotein profile of relapsing-remitting (RR) MS patients, progressive MS pat

289 ive (PP) MS while the other three focused on relapsing-remitting (RR) MS.

290 Most patients with relapsing-remitting (RR) multiple sclerosis (MS) who rec

291 rations were measured by ELISA in cases with relapsing-remitting (RR)-MS (n=81), secondary progressiv

292 still possible, and even favored, in stable relapsing-remitting (RR-MS) patients, whereas it was abs

293 e measured in 440 patients with MS (311 with relapsing-remitting [RR] MS, 92 with secondary-progressi

294 ical trial of AHSCT for patients with active relapsing remitting (RRMS) and secondary progressive MS

295 PMS) patients, but not in a third cohorts of relapsing-remitting (RRMS) patients.

296 he article presents a case of a patient with relapsing-remitting severe BBE.

297 re aged 42-83 years and were referred with a relapsing remitting syndrome of fever (94%), constitutio

298 nical course of multiple sclerosis (MS) from relapsing-remitting to secondary progressive have not be

299 lindromic rheumatism often being viewed as a relapsing-remitting variant of RA.

300 ohort of 18 MS patients (9 progressive and 9 relapsing-remitting) was compared to healthy controls an